Home > Oncology > ESMO 2021 > Gastrointestinal Cancer > Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC

Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC

Presented By
Dr Pei-Rong Ding, Sun Yat-sen University Cancer Center, China
Conference
ESMO 2021
Trial
Phase 3, CONVERT
Results from the phase 3, open label CONVERT study suggest neoadjuvant chemotherapy to be non-inferior to neoadjuvant chemoradiation in patients with locally advanced rectal cancer (LARC). Combined chemoradiation therapy is currently the standard practice for LARC with uninvolved mesorectal fascia. Results from the FOWARC trial were promising for neoadjuvant chemotherapy, but this trial (n=165 patients/arm) was not powered for non-inferiority [1]. The CONVERT study (NCT02288195) was conducted to compare neoadjuvant chemotherapy (capecitabine, oxaliplatin) with standard chemoradiotherapy with capecitabine for these patients. Dr Pei-Rong Ding (Sun Yat-sen University Cancer Center, China) presented the first results [2]. A total of 663 patients with LARC within 12 cm from the anal verge and uninvolved mesorectal fascia we...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on